Key Highlights
- Continued strength in neuromodulation and energy-based stimulation devices
- Expansion into neurological and neuropsychiatric applications
- Continued aesthetic and dermatology device activity
- Widespread use of sham-controlled and matched-pair exploratory designs
- Diversification across diagnostic, therapeutic, and monitoring device categories
The July 2026 MFDS medical device approvals reflect a clear concentration around neuromodulation and other energy-based stimulation technologies, alongside continued activity in aesthetic devices. Of the eight devices approved during the month, five involve electrical, ultrasound, or electromagnetic stimulation, pointing to sustained clinical interest in this category.
Several approved studies target neurological and neuropsychiatric indications: a transcranial direct current stimulation device evaluated for cognitive and emotional changes in autoimmune encephalitis, a medical electromagnetic field generator studied in adolescents with treatment-resistant depression, and a low-frequency electrical stimulator assessed for lower-limb motor recovery after early subacute stroke. This marks a notable expansion of energy-based devices beyond their more established aesthetic and monitoring applications into central nervous system and mental health indications.
Aesthetic and dermatology devices also remained active, with a general-purpose electrosurgical device and a focused ultrasound stimulation system each evaluated for temporary improvement of facial wrinkles or skin laxity against comparator devices such as Thermage FLX, reflecting the continued maturity of Korea’s aesthetic device market and its reliance on head-to-head comparative designs.
The remaining approvals covered a diagnostic device (an electronic thermometer using heat-flux-based temporal artery measurement) and a hemostatic device for liver resection surgery, further illustrating the breadth of applications under review this month. Across nearly all studies, sham-controlled, matched-pair, or active-controlled exploratory designs were used, underscoring the emphasis on rigorous comparative evidence even for smaller, single-center studies.
Overall, the July 2026 approval data suggests that Korea’s medical device market is extending established energy-based and aesthetic device expertise into new neurological and psychiatric applications, while diagnostic and surgical devices continue to round out a diversified pipeline.